TMO - Medical Equipment Maker Thermo Fisher Scientific Clocks 7% Decline In Q4 Organic Sales Issues Subdued Annual Outlook | Benzinga
Wednesday, Thermo Fisher Scientific Inc (NYSE: TMO) posted a fourth-quarter revenue of $10.89 billion, down 5% year-on-year (Y/Y), beating the consensus of $10.73 billion.
Organic revenue was 7% lower, Core organic revenue growth declined 4%, and COVID-19 testing revenue was $0.05 billion.
Revenue from the Life Sciences Solutions Segment declined by 18.9% to $2.47 billion. Analytical Instruments Segment sales were up 8.5% to ...